In contrast, αhPD1-hIL12mut2 treatment significantly suppressed tumor growth (Fig. 4d), suggesting that IL-12 enhances the antitumor efficacy of anti-PD-1 antibodies in the form of a T-cell-targeting fusion protein. This evidence concerns the gene PDCD1 and neoplasm.